论文部分内容阅读
目的 对罗氏芬与先力腾序贯治疗儿科感染进行成本效益分析。方法 采用开放式对照的研究方法，将５１ 例中度感染患儿分三组： 罗氏芬、先力腾序贯治疗组， 静脉用罗氏芬组和口服先力腾组。从药品经济学角度对临床疗效、安全性和医疗费用进行综合评价。结果 三组疗效无显著性差异。口服用药最经济， 罗氏芬、先力腾序贯治疗显示较高的成本效益， 采用序贯治疗对门诊治疗患儿每天可节省费用５６ 元， 住院患儿每天可节省费用５９ 元。结论 罗氏芬、先力腾序贯治疗儿科中度感染有明显成本效益优势。先力腾疗效可靠， 治疗费用低， 是第三代头孢序贯治疗的较理想的口服接续药。序贯治疗是值得提倡的方法。
Objective To analyze the cost-benefit of sequential treatment of pediatric infection with Rochefen and Zeretin. Methods In an open-label study, 51 children with moderate infection were divided into three groups: Rocephin, the first Li-Teng sequential treatment group, the Rocephin intravenous group, and the E-lengteng group. Comprehensive evaluation of clinical efficacy, safety and medical costs from the perspective of pharmaceutical economics. Results There was no significant difference between the three groups. Oral medication is the most economical, Rocephin, first Li Teng sequential treatment showed a higher cost-effective, sequential treatment of children outpatient treatment can save 56 yuan a day, hospitalized children can save 59 yuan a day. Conclusion Rochefen, the first force of sequential treatment of moderate infections in children has obvious cost-effectiveness advantage. The first force Teng effective and reliable, low cost of treatment is the third generation of cephalosporin sequential treatment of the ideal oral continuum. Sequential treatment is worth promoting.